Transcode Therapeutics Inc

Proposal 1 requests shareholder approval under Nasdaq Listing Rule 5635 for the potential issuance of up to 14,658,054 shares of Common Stock upon conversion of Series A and Series B Preferred Stock issued in connection with the Acquisition of Polynoma and related $25 million investment by DEFJ (CK Life Sciences affiliate). Management seeks approval because the preferred conversion would cause issuance in excess of Nasdaq thresholds (over 19.99%) and thus requires shareholder approval for listing compliance and to avoid potential redemption or repurchase triggers. The board recommends the proposal because approval permits conversion that would reclassify the Series A from temporary equity to equity improving stockholders’ equity and Nasdaq listing compliance, and because failure to obtain approval by December 31, 2026 may permit redemption/repurchase rights that would materially harm the company’s financial condition. The Company retained financial and legal advisers and considered alternative structures; the board also relied on a fairness opinion. The conversion terms include conversion ratios (Series A and B convert into 10,000 shares each) and various beneficial ownership limits, registration rights, and repurchase rights and are accompanied by contingent milestone obligations. The proposal is routine for completing the Acquisition financing but involves significant dilution and change-of-control aspects, concentrating ownership with DEFJ; it therefore raises governance and shareholder value considerations such as dilution, potential control transfer, and reliance on CVRs and registration processes. Analysts should weigh the near-term recapitalization benefits and Nasdaq compliance against dilution and governance concentration risks, as well as the contingent liabilities represented by milestones and repurchase triggers.

Proposal 2 requests shareholder approval under Nasdaq Listing Rule 5635(a) for conversion of 1,214,204 shares of Series C Preferred Stock issued to Unleash as consideration for an exclusive license to an oncolytic immunotherapy program and related technology. Management seeks approval to comply with Nasdaq rules because the conversion could result in beneficial ownership of greater than 19.99% by the holder absent approval. The Series C converts one-for-one into Common Stock following shareholder approval and includes a 4.99% beneficial ownership limitation per holder until approval. The board recommends approval because it enables the licensing transaction consideration to be converted into Common Stock and supports the Company’s strategic expansion into oncolytic immunotherapy; approval also aligns with registration rights and funding needs. The principal issues for investors are dilution, the strategic merits of the Unleash asset acquisition, and the shareholder protections in the Series C terms (beneficial ownership cap, limited voting rights). Analysts should assess whether the license and associated personnel/rights materially strengthen the pipeline relative to dilution risk.

Proposal 3 seeks shareholder approval under Nasdaq Listing Rule 5635(d) to permit the issuance of Common Stock to Yorkville under a Standby Equity Purchase Agreement (SEPA) and upon conversion of Convertible Notes issued in connection with two prepaid advances (first note $1.0M already issued; second $5.0M contingent on registration effectiveness and shareholder approval). The SEPA allows the Company to sell up to $14M of Common Stock at the Company’s option, and Yorkville agreed to provide up to $6M in prepaid advances (Convertible Notes). Under Nasdaq rules the Company cannot issue to Yorkville more than an Exchange Cap of 183,301 shares (19.99%) without shareholder approval, and approval would allow issuance in excess of that cap for up to $20M. The financing provides near-term liquidity and optionality but raises concerns about dilution, variable-rate conversion mechanics tied to VWAP, protective floor prices, potential high conversion discounts, and default provisions (increasing interest to 18% and possible amortization events). The board recommends approval to access funding and preserve Nasdaq listing criteria; analysts should consider the dilutive impact, the conversion price mechanics relative to market volatility, and the Company’s potential reliance on opportunistic equity sales versus alternative financing.

Proposal 5 requests stockholder approval to increase the share reserve under the 2021 Stock Option and Incentive Plan by 1,734,262 shares to a new Initial Limit of 1,949,894 shares, plus annual increases. Management argues the increase is necessary to grant equity awards needed to attract, retain and motivate employees and align interests with stockholders. The plan includes standard terms for options, RSUs, SARs, and cash awards, and contemplates limits on annual director compensation. The board recommends approval; analysts should weigh the dilutive impact versus talent retention needs, evaluate historical equity burn rates and grant practices, and examine whether compensation targets are consistent with peers. The amendment also allows repricing of awards without stockholder approval, subject to committee discretion, which may raise corporate governance concerns.

Proposal 7 seeks shareholder authorization to permit adjournment of the Annual Meeting to solicit additional proxies if Proposals 1, 2, 3 or 5 do not receive sufficient votes or if Nasdaq approval of the Initial Listing Application is pending. This is a routine procedural measure often recommended in connection with proposals requiring shareholder approval. Management argues that the adjournment would allow additional time to solicit votes and to obtain necessary approvals (e.g., Nasdaq), thereby avoiding the potentially material adverse consequences of failing to secure approvals on schedule. Analysts should note that approval would give management flexibility to continue soliciting until approvals are obtained, but does not change the substantive rights or outcomes of the underlying proposals.